Answers are grounded in this paper and cite their sources.
The interconnected antioxidant systems of cancer cells, centered on the glutathione and thioredoxin axes, constitute a promising therapeutic vulnerability. However, simultaneous disruption of both axes by dual‐inhibitor regimens is hampered by pharmacokinetic asynchrony. Herein, we report squaraine‐based photocatalysts as a single‐agent modality that concurrently disrupts these interconnected antioxidant systems in cancer cells. Upon 635 nm light irradiation, IITC depletes intracellular NADPH and GSH through photocatalytic oxidation coupled with type I/II photosensitization. NADPH depletion deprives the reductive coenzyme of thioredoxin reductase in the thioredoxin axis, while glutathione oxidation collapses the central antioxidant axis. Consequently, IITC ablates both antioxidant axes concurrently and exerts potent phototherapeutic anticancer activity in vitro and in vivo. Importantly, during phototherapy IITC undergoes self‐immolation into nontoxic degraded fragments, thereby avoiding phototoxicity post‐treatment. This self‐eliminating, metabolism‐targeted photocatalytic strategy establishes a new avenue for safe and efficient cancer phototherapy.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: